Twist Bioscience and Ginkgo Bioworks Rise on Drug Discovery Agreements with Lilly TuneLab
Shares of Twist Bioscience (NASDAQ: TWST) and Ginkgo Bioworks (DNA) increased following announcements that both companies have entered into agreements with Lilly TuneLab, a drug discovery platform established by Eli Lilly. The partnerships aim to leverage the biotech firms' capabilities in synthetic biology for advancing pharmaceutical research. Twist Bioscience will collaborate on DNA synthesis and sequencing projects under its agreement with Lilly TuneLab. Ginkgo Bioworks is also set to work closely with the platform, though specific details of their collaboration were not disclosed at this time. These partnerships are seen as strategic moves that could enhance both companies' visibility in the biotech sector. The market reaction reflects optimism about these collaborations and their potential for long-term value creation.
Topics: biotech collaboration drug discovery